CXCR4 and Miyoshi myopathy: In this perspective, C-X-C-motif chemokine receptor 4 (CXCR4) has emerged as a relevant theranostic biomarker in MM and other malignancies, and the theranostic couple “68Ga-pentixafor/177Lu-pentixather” holds promise to move the field forward [42,43].